In vitro studies suggest that certain probiotic bacterial strains have potential activity against opportunistic infections such as Candida. There are few in vivo trials using probiotics as a single treatment for acute Candida vulvovaginitis (CV). In this open-label, proof-of-concept study, selected Lactobacillus strains were tested in women with acute Candida vaginitis. Twenty women diagnosed with proven, symptomatic CV were instructed to administer a vaginal probiotic gel with L. plantarum YUN-V2.0, L. pentosus YUN-V1.0 and L. rhamnosus YUN-S1.0 for 10 consecutive days. Vaginal rinsing fluid, vaginal culture swab and vaginal smear for fresh wet-mount microscopy were collected before and 7, 14 and 28 days after start of treatment. On average, participating women were 39 years old and had an history of 5 vaginal infections of which 95% was CV. Nine women (45%) completed the study without the need of rescue medication. Women who needed rescue treatment experienced twice as much Candida infections in the past. A negative correlation was found between the clinical composite score and the time to use rescue medication (R² = 0.127). Seventy-four per cent of participants found the study gel comfortable to use, and 42% of all women would use the tested gel again for this indication. Forty-five per cent of women were treated successfully for acute CV with a novel vaginal gel containing 3 selected Lactobacillus strains. Patients needing rescue treatment were suffering from more severe and long-standing disease. These results warrant for further testing of this new product, especially of its potential in cases with mild to moderate severity, as an adjuvant to antimycotics or as a preventive measure in women with recurrent vulvovaginal candidosis.

体外研究表明，某些益生菌菌株对机会感染如念珠菌具有潜在的活性。很少有使用益生菌作为单一治疗急性念珠菌性阴道炎（CV）的体内试验。在这项开放性概念验证研究中，对患有急性念珠菌性阴道炎的妇女测试了所选的乳酸杆菌菌株。指导20名经确诊，有症状的CV妇女使用植物乳杆菌YUN-V2.0，戊糖乳杆菌YUN-V1.0和鼠李糖乳杆菌YUN-S1.0阴道益生菌凝胶连续10天。在治疗开始前，治疗后第7、14和28天收集阴道冲洗液，阴道培养拭子和阴道涂片进行新鲜的湿式显微镜检查。平均而言，参与研究的女性为39岁，有5次阴道感染史，其中95％为CV。九名妇女（45％）完成了这项研究，不需要急救药物。过去需要抢救治疗的女性感染假丝酵母的人数是以前的两倍。在临床综合评分与使用急救药物的时间之间发现负相关（R ² = 0.127）。74％的参与者认为该研究凝胶使用起来舒适，而42％的女性将再次使用该测试凝胶用于该适应症。45％的女性用包含3种选定的乳酸杆菌菌株的新型阴道凝胶成功治疗了急性CV 。需要抢救治疗的患者患有更加严重和长期的疾病。这些结果保证了对该新产品的进一步测试，特别是对于轻度至中度严重情况的潜能，作为抗真菌药的佐剂或对复发性阴道念珠菌病女性的预防措施。